Wearable activity monitors used in DMD study; NIH seeks Alzheimer's biomarkers in Down's patients;

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Invitae builds out cancer and epilepsy testing menus; Illumina gets in on autism research. More | Follow @EmilyWFierce

> Catabasis Pharmaceuticals ($CATB) and ActiGraph are starting an observational study of Duchenne muscular dystrophy patients' daily physical activity using activity monitoring wearables from the latter. More

> The National Institutes of Health has launched an initiative to identify Alzheimer's biomarkers in people with Down syndrome. People with Down syndrome have Alzheimer's-related brain changes that can lead to early dementia. More

> University of Georgia researchers have developed a test of visual processing speed to identify brain function problems. More

Biotech News

@FierceBiotech: UCSD team targeting new stress pathway in Alzheimer's program. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: The Brent Saunders argument that he's opposed to R&D is a bit specious. $AGN acquires late-stage assets, avoids discovery. Not anti-research. | Follow @JohnCFierce

> KaloBios is back from the dead after Shkreli swoops in to 'save' its lead drug. Story

> Pfizer snags U.S. rights to Cellectis' white-hot CAR-T therapy. Article

> Silicon Valley VC shop Andreessen Horowitz sets up $200M bio fund. Report

Pharma News

@FiercePharma: Zoetis ups the ante in prevention with new flu vaccine and flea fighter for dogs. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Baxalta Singapore plant gets FDA OK to produce Advate. Article | Follow @EricPFierce

> Adapt's new bargain-priced OD antidote enters contentious market. News

> Post-AASLD, Gilead's lead in hep C looks as solid as ever: analysts. Item

> Express Scripts rolls out value-based pricing for cancer meds. Report

CRO News

> WuXi lands a lead role in Genomics England's big project. Item

> Parexel touts its IT-enabled R&D services amid company shakeup. Report

> Fast-growing Charles River trades $36M for a drug discovery outfit. Article

> PRA expands in Singapore with eyes on Asian growth. Story

Pharma Manufacturing News

> Merck KGaA JV set to start producing drugs in remote Algerian village. More

> Shortages, shifts in sterile injectable market lead some prices to soar. Story

> Drug distributor recalls anxiety drug after wrong med found in a bottle. Report

> With pharma cargo theft on the rise, Thanksgiving can be a risky holiday. Item

> Hikma says FDA has closed out warning letter for EU injectables plant. Article

Pharma Asia News

> India's Supreme Court wants stricter oversight of MSD, GSK HPV clinical trials. More

> Price controls loom for generic drugs in India next year. Report

> Samsung Bioepis biosimilar may get nod in Europe. Story

> Mundipharma licenses Spectrum's NHL treatment, picks up Japan affiliate. Item

> GSK beefing up vaccine business in India. Article

Suggested Articles

The two companies also plan to identify new potential targets and therapeutic candidates for inflammatory bowel disease, or IBD.

This would allow centralized, lab-based diagnostic hardware to process blood samples at scale, screening patients for previous infections.

GlaxoSmithKline and AstraZeneca are considering forming a joint lab to help the U.K. expand its supplies for COVID-19 testing, according to Bloomberg.